Does Wegovy Decrease Appetite — and How Long Does It Take to Notice?

The first few weeks: what hunger actually feels like on Wegovy

Picture this: you've started your first Wegovy pen at 0.25mg, you're waiting for something to happen, and for a while it feels like nothing much has. That's normal. The starting dose is there to let your system adjust, not to deliver the full appetite effect straight away. Most people describe the early weeks as a quiet version of what comes later, meals feel slightly less urgent, the urge to snack in the evening softens a little, but the dramatic 'I completely forgot to eat lunch' moment usually arrives later in the titration.

What the science explains is that semaglutide binds to GLP-1 receptors in two key places: in the hypothalamus, where hunger and satiety signals are processed, and in the gut, where it slows gastric emptying so food stays in the stomach longer. The result isn't just 'feeling full faster', it's a genuine reduction in the baseline drive to eat. In the STEP 1 clinical trial, published in the New England Journal of Medicine, adults using semaglutide 2.4mg lost an average of around 15% of body weight over 68 weeks, a figure that reflects the sustained appetite suppression across the full treatment period. By the time most participants reached their maintenance dose, eating substantially less had become the norm rather than an effort.

The practical experience varies. Some people lose interest in foods they previously craved. Others find their portion size shrinks naturally. A smaller group notices the effect mainly at mealtimes rather than as a wholesale disappearance of hunger. All of these responses sit within the expected range.

Why hunger often drops again each time the dose goes up

One pattern our prescribers hear about most weeks: people who felt the appetite suppression plateau at one dose are surprised to find it deepens again after a dose increase. This is consistent with how semaglutide works, higher doses produce stronger receptor activation, and for many people that translates directly into a renewed reduction in hunger and food-seeking behaviour.

The Wegovy dosing schedule moves through 0.25mg, 0.5mg, 1.0mg, 1.7mg and 2.4mg, titrated approximately every four weeks by the prescriber. The dose your prescriber is working towards is the one the licence and trial data are built around, 2.4mg for most adults, though the 7.2mg pen approved by the MHRA in April 2026 extends that ceiling further. Understanding how dose increases affect results is genuinely useful context here, because the appetite curve and the weight-loss curve tend to track each other as the dose rises.

The trade-off is that dose increases can temporarily bring GI side effects back to the surface, nausea, burping, or feeling full to the point of discomfort. These tend to settle within a week or two. Worth knowing about before the next pen arrives.

What happens if appetite doesn't decrease, or decreases too much

A smaller number of people find that appetite suppression is minimal even at higher doses. This isn't a sign that the medicine isn't working in other ways, but it is worth raising with your prescriber rather than assuming it's the expected experience. Separately, some people find hunger drops so sharply that eating enough protein and maintaining adequate nutrition becomes its own challenge, something the NHS semaglutide guidance addresses by encouraging patients to prioritise nutrient-dense food even when appetite is low.

There's also an occasionally reported pattern that runs the other way: a temporary return of appetite, particularly after a missed dose or during illness. If that sounds familiar, the question of why appetite sometimes increases on Wegovy has its own detailed answer. And for people who notice other unexpected changes alongside their appetite shift, the effect of Wegovy on libido is another area where the evidence is sometimes misread.

One practical note: the pen itself, which arrives via DPD in a plain unbranded box, contains four weeks of doses. Once you're injecting weekly and the dose has settled, many people stop thinking about the mechanism entirely. The appetite change has just become the new baseline.

When to talk to your prescriber about appetite changes

Appetite suppression is expected. Appetite suppression so severe that you're struggling to eat anything, or accompanied by persistent nausea, vomiting or significant abdominal pain, is a reason to get in touch rather than push through. The MHRA has highlighted acute pancreatitis as an uncommon but serious consideration for GLP-1 medicines, severe stomach pain that radiates to the back warrants prompt medical attention, not watchful waiting. Report any suspected side effects through the MHRA Yellow Card scheme.

Appetite changes should also prompt a conversation if they feel like they're affecting your relationship with food in ways that go beyond reduced hunger, restriction that feels compulsive, anxiety around eating, or a pattern that worries you. These aren't common outcomes, but they matter.

If you're considering Wegovy and want to understand whether it's clinically suitable for your situation, our Wegovy overview covers the full eligibility picture. Pricing context is on our Wegovy prices page. When you're ready to find out whether you'd be approved, start your free consultation and a GPhC-registered prescriber will review your answers the same day.